Adaptive Biotechnologies Corporation Overview
Pro stress-test →Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease through proprietary immune receptor sequencing and analysis that decodes T-cell and B-cell receptors to identify signatures of immune response. The company reported full-year 2025 revenue of $277.0 million, a 55% increase year-over-year, with the MRD business driving growth.
Strategic Profile
Pro stress-test →Adaptive leverages proprietary immune receptor sequencing technology to decode the genetic information of T-cell and B-cell receptors. The company operates two business segments: clonoSEQ MRD (Minimal Residual Disease) diagnostics for blood cancers and immune medicine development, with a path to companywide profitability in 2026.
Competitive Landscape
Pro stress-test →The biotechnology and pharmaceutical industries are characterized by intense competition, with many companies pursuing advancements in immune medicine and larger companies with greater resources potentially overshadowing its offerings. There are concerns about incoming competition in the DLBCL space, which may affect market penetration.
Industry Context
Adaptive Biotechnologies Corporation operates in Clinical-stage Biotechnology / Immune Medicine / Molecular Diagnostics.
Key facts
Founded: 2009 · Headquarters: Seattle, US · Employees: ~620 · Revenue: $277.0M · Market cap: $1.4B